We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vertex Pharmaceuticals (VRTX) Stock Moves -1.00%: What You Should Know
Read MoreHide Full Article
In the latest close session, Vertex Pharmaceuticals (VRTX - Free Report) was down 1% at $455.45. This change was narrower than the S&P 500's daily loss of 1.13%. Elsewhere, the Dow lost 1.79%, while the tech-heavy Nasdaq lost 1.3%.
Prior to today's trading, shares of the drugmaker had gained 5.91% outpaced the Medical sector's gain of 3.07% and the S&P 500's gain of 3.55%.
Market participants will be closely following the financial results of Vertex Pharmaceuticals in its upcoming release. The company is expected to report EPS of $4.24, up 133.05% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $2.88 billion, up 8.85% from the prior-year quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $17.82 per share and a revenue of $11.91 billion, representing changes of +4142.86% and +8.06%, respectively, from the prior year.
Any recent changes to analyst estimates for Vertex Pharmaceuticals should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 0.08% higher within the past month. Vertex Pharmaceuticals is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note Vertex Pharmaceuticals's current valuation metrics, including its Forward P/E ratio of 25.82. This valuation marks a premium compared to its industry average Forward P/E of 20.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 78, placing it within the top 32% of over 250 industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Vertex Pharmaceuticals (VRTX) Stock Moves -1.00%: What You Should Know
In the latest close session, Vertex Pharmaceuticals (VRTX - Free Report) was down 1% at $455.45. This change was narrower than the S&P 500's daily loss of 1.13%. Elsewhere, the Dow lost 1.79%, while the tech-heavy Nasdaq lost 1.3%.
Prior to today's trading, shares of the drugmaker had gained 5.91% outpaced the Medical sector's gain of 3.07% and the S&P 500's gain of 3.55%.
Market participants will be closely following the financial results of Vertex Pharmaceuticals in its upcoming release. The company is expected to report EPS of $4.24, up 133.05% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $2.88 billion, up 8.85% from the prior-year quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $17.82 per share and a revenue of $11.91 billion, representing changes of +4142.86% and +8.06%, respectively, from the prior year.
Any recent changes to analyst estimates for Vertex Pharmaceuticals should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 0.08% higher within the past month. Vertex Pharmaceuticals is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note Vertex Pharmaceuticals's current valuation metrics, including its Forward P/E ratio of 25.82. This valuation marks a premium compared to its industry average Forward P/E of 20.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 78, placing it within the top 32% of over 250 industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.